# Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

> **NCT00146588** · NA · COMPLETED · sponsor: **Craig A. Bunnell, MD, MPH** · enrollment: 55 (actual)

## Conditions studied

- Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00146588
- **Lead sponsor:** Craig A. Bunnell, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146588, "Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00146588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*